Identifying the targets for treatment of liver fibrosis and hepatocellular carcinoma from both Western medicine and Chinese medicine

Chinese Journal of Integrative Medicine

Volumn 18, Issue 4, 2012, Pages 245-249

  Gong, Yuewen ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Bone morphogenetic protein; Hepatocellular carcinoma; Integrative medicine; Liver fibrosis

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN 4; MITOGEN ACTIVATED PROTEIN KINASE; PAEONIFLORIN; SAIKOSAPONIN; SAPONIN; SMAD PROTEIN; SORAFENIB; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CHINESE MEDICINE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INTEGRATIVE MEDICINE; LIVER CELL CARCINOMA; LIVER FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; TRADITIONAL MEDICINE; WESTERN MEDICINE;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MEDICINE, CHINESE TRADITIONAL; MOLECULAR TARGETED THERAPY;

EID: 84862740540     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-012-1062-6     Document Type: Article

References (41)

1. Friedman SL. Liver fibrosis - from bench to bedside. J Hepatol 2003;38 Suppl 1:S38-S53.
2. Gibbons GF, Wiggins D, Brown AM, Hebbachi AM. Synthesis and function of hepatic very-low-density lipoprotein. Biochem Soc Trans 2004;32:59-64. (Pubitemid 38283014)
3. Fausto N, Laird AD, Webber EM. Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. FASEB J 1995;9:1527-1536.
4. Jungermann K, Katz N. Functional specialization of different hepatocyte populations. Physiol Rev 1989;69:708-764. (Pubitemid 19184848)
5. Groothuis GM, Meijer DK. Hepatocyte heterogeneity in bile formation and hepatobiliary transport of drugs. Enzyme 1992;46:94-138. (Pubitemid 23032629)
6. Zhang L, Zhang QM, Wang YG, Yu DL, Zhang W. The traditional Chinese medicine pattern of the six-zang and six-fu organs can be simplified into the pattern of five-zang and one-fu organs. J Tradit Chin Med 2011;31:147-151.
7. Li ZG, Chen G. Comparative study on WHO Western Pacific Region and World Federation of Chinese Medicine Societies International Standard Terminologies on Traditional Medicine: six-meridian pattern identification/syndrome differentiation. J Chin Integr Med (Chin) 2011;9:1270-1276.
8. Mou X, Liu WH, Zhou DY, Liu YH, Hu YB, Ma GL, et al. Association of Chinese medicine constitution susceptibility to diabetic nephropathy and transforming growth factorbeta1 (T869C) gene polymorphism. Chin J Integr Med 2011;17:680-684.
9. Qi ZX, Chen L. Effect of Chinese drugs for promoting blood circulation and eliminating blood stasis on vascular endothelial growth factor expression in rabbits with glucocorticoid-induced ischemic necrosis of femoral head. J Tradit Chin Med 2009;29:137-140.
10. Friedman SL. Hepatic stellate cells. Prog Liver Dis 1996;14:101-130. (Pubitemid 26381337)
11. Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993;328:1592-1598. (Pubitemid 23151919)
12. Zamani N, Brown CW. Emerging roles for the transforming growth factor-{beta} superfamily in regulating adiposity and energy expenditure. Endocr Rev 2011;32:387-403.
13. Chang H, Brown CW, Matzuk MM. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 2002;23:787-823. (Pubitemid 35454589)
14. Attisano L, Wrana JL. Signal transduction by members of the transforming growth factor-beta superfamily. Cytokine Growth Factor Rev 1996;7:327-339. (Pubitemid 27198069)
15. Shen H, Huang G, Hadi M, Choy P, Zhang M, Minuk GY, et al. Transforming growth factor-beta1 downregulation of Smad1 gene expression in rat hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2003;285:G539-G546. (Pubitemid 37021813)
16. Fan J, Shen H, Sun Y, Li P, Burczynski F, Namaka M, et al. Bone morphogenetic protein 4 mediates bile duct ligation induced liver fibrosis through activation of Smad1 and ERK1/2 in rat hepatic stellate cells. J Cell Physiol 2006;207:499-505.
17. Fan J, Shen H, Dai Q, Minuk GY, Burzynski FJ, Gong Y. Bone morphogenetic protein-4 induced rat hepatic progenitor cell (WB-F344 cell) differentiation toward hepatocyte lineage. J Cell Physiol 2009;220:72-81.
18. Liu P, Hu YY, Liu C, Xu LM, Liu CH, Sun KW, et al. Multicenter clinical study on Fuzhenghuayu Capsule against liver fibrosis due to chronic hepatitis B. World J Gastroenterol 2005;11:2892-2899. (Pubitemid 40790056)
19. Chen Y, Chen Q, Lu J, Li FH, Tao YY, Liu CH. Effects of Danggui Buxue Decoction on lipid peroxidation and MMP-2/9 activities of fibrotic liver in rats. Chin J Integr Med 2009;15:435-441.
20. Shen WS, Yang HZ, Hong Q, Zhang YQ, Xie HP, Bian Z. Two-year observation of the clinical efficacy in treating chronic hepatitis B patients with Ganxian Recipe and lamivudine. Chin J Integr Med 2005;11:5-10. (Pubitemid 40756361)
21. Wang L, Wang J, Wang BE, Xiao PG, Qiao YJ, Tan XH. Effects of herbal compound 861 on human hepatic stellate cell proliferation and activation. World J Gastroenterol 2004;10:2831-2835. (Pubitemid 39302999)
22. Cheung KF, Ye DW, Yang ZF, Lu L, Liu CH, Wang XL, et al. Therapeutic efficacy of traditional Chinese medicine 319 Recipe on hepatic fibrosis induced by carbon tetrachloride in rats. J Ethnopharmacol 2009;124:142-150.
23. Sakaida I, Matsumura Y, Akiyama S, Hayashi K, Ishige A, Okita K. Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol 1998;28:298-306. (Pubitemid 28116438)
24. Shimizu I. Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma. J Gastroenterol Hepatol 2000;15 Suppl:D84-D90. (Pubitemid 30190730)
25. Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, et al. Effects of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999;29:149-160. (Pubitemid 29023997)
26. Fan J, Li X, Li P, Li N, Wang T, Shen H, et al. Saikosaponin-d attenuates the development of liver fibrosis by preventing hepatocyte injury. Biochem Cell Biol 2007;85:189-195. (Pubitemid 46841687)
27. Yuspa SH, Dlugosz AA, Cheng CK, Denning MF, Tennenbaum T, Glick AB, et al. Role of oncogenes and tumor suppressor genes in multistage carcinogenesis. J Invest Dermatol 1994;103:S90-S95.
28. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14:818-829. (Pubitemid 351757205)
29. WHO. World Health Organization Fact sheets: Cancer. 2012; Available from: http://www.who.int/mediacentre/factsheets/fs297/en/.
30. Pollicino T, Saitta C, Raimondo G. Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis 2011;32:1122-1132.
31. Blonski W, Reddy KR. Hepatitis C virus infection and hepatocellular carcinoma. Clin Liver Dis 2008;12:661-674, x. (Pubitemid 351952471)
32. Lok AS. Hepatitis B: liver fibrosis and hepatocellular carcinoma. Gastroenterol Clin Biol 2009;33:911-915.
33. Cao ZY, Chen XZ, Liao LM, Peng J, Hu HX, Liu ZZ, et al. Fuzheng Yiliu Granule inhibits the growth of hepatocellular cancer by regulating immune function and inducing apoptosis in vivo and in vitro. Chin J Integr Med 2011;17:691-697.
34. Tian HQ, Li HL, Wang B, Liang GW, Huang XQ, Huang ZQ, et al. Treatment of middle/late stage primary hepatic carcinoma by Chinese medicine comprehensive therapy: a prospective randomized controlled study. Chin J Integr Med 2010;16:102-108.
35. D'Alessandro N, Poma P, Montalto G. Multifactorial nature of hepatocellular carcinoma drug resistance: could plant polyphenols be helpful? World J Gastroenterol 2007;13:2037-2043. (Pubitemid 46795838)
36. Ranieri G, Gadaleta-Caldarola G, Goffredo V, Patruno R, Mangia A, Rizzo A, et al. Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development. Curr Med Chem 2012 [Epub ahead of print].
37. Hibasami H, Iwase H, Yoshioka K, Takahashi H. Glycyrrhetic acid (a metabolic substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelotic leukemia and stomach cancer cells. Int J Mol Med 2006;17:215-219.
38. Anis KV, Rajeshkumar NV, Kuttan R. Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol 2001;53:763-768. (Pubitemid 32457828)
39. Sun Y, Cai TT, Shen Y, Zhou XB, Chen T, Xu Q. Si-Ni-San, a traditional Chinese prescription, and its active ingredient glycyrrhizin ameliorate experimental colitis through regulating cytokine balance. Int Immunopharmacol 2009;9:1437-1443.
40. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, et al. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 2006;44:240-251. (Pubitemid 44049156)
41. Shi GM, Xu Y, Fan J, Zhou J, Yang XR, Qiu SJ, et al. Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol 2008;134:1155-1163.